«With breakthrough technology, clinical
stage product candidates, an extensive intellectual property estate, and a strong and dedicated team, ViaCyte has all the pieces to advance a transformative new life - saving approach that could help hundreds of thousands of people with high - risk type 1 diabetes around the world.»
Not exact matches
The report points to a number of factors driving big pharma companies» struggles with netting strong returns, including a dearth of late -
stage pipeline
candidates and diversified
product portfolios that aren't necessarily spreading risk.
The company's lead
candidate is Trevyent, a development
stage drug
product that utilizes SteadyMed's PatchPump technology to administer treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension.
«We are very confident in its X-ALD
candidate and we look forward to the next
stages of development for this
product.»
For example, Matt Krause, director of human resources at CV Therapeutics, says, «Our research programs include multiple, cutting - edge cardiovascular
product candidates in various
stages of clinical trials and preclinical programs, all of which rely heavily on the contributions from our many B.S. - and M.S. - level scientists.»
ViaCyte's PEC - EncapTM (also known as VC - 01TM)
product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical -
stage development.
Each company has contributed
product candidates to the collaboration: Sanofi Pasteur will contribute HSV - 529, a clinical -
stage replication - defective HSV vaccine
product candidate, and Immune Design will contribute G103, its preclinical trivalent vaccine
product candidate.
Given the breadth of our species coverage, and we have the broadest species coverage of any of the animal health companies, naturally then you look at
products in the pipeline across all the species areas, there are robust
candidates that are at various
stages of development and progressing regulatory approval timelines.
Under the leadership of lead
product data scientist Jessica Kirkpatrick, job search platform Hired analyzed its user data — including more than 100,000 job offers among 15,000
candidates and 3,000 companies, and found that the wage gap can wreak havoc on a woman's career at the job offer
stage.